Donald Kerr Symposium

Register for the Symposium

Abstract submissions are now closed.

ABOUT

On June 15-16, 2017, the University of Michigan will launch the Donald Kerr Symposium, to be held every two years. In this CE series, we will provide comprehensive coverage of emerging clinical topics and translational research in Oral Pathology and Oral Medicine. Dr. Donald A. Kerr was a past president and co-founder of the American Academy of Oral Pathology and a past president of the American Academy of Periodontology. The symposium is a tribute to his vision and leadership in advancing oral healthcare.

The inaugural Donald Kerr Symposium will provide a panoramic view of the current landscape of personalized medicine in oral, head and neck cancer. The symposium brings together internationally renowned experts who have made seminal contributions to the emerging field of personalized diagnosis and treatment of patients with oral, head and neck cancer. The topics include HPV, clinical stratification, cancer biology and immunotherapy. The symposium will be of interest to healthcare professionals and scientists who are or want to be involved in the personalized diagnosis and management of patients with oral, head & neck cancer.

We look forward to seeing you in beautiful Ann Arbor with its vibrant community.

LEARNING OBJECTIVES

By participating in this CE activity, individuals will understand and be able to implement into their practice:

  • Updated epidemiology studies
  • Precision-medicine guided stratification and molecular diagnostic approaches
  • Novel immunotherapy findings – Latest research findings

DENTIST / PHYSICIAN / SCIENTIST
Early Bird Fee: $270
After May 15, 2017: $295

AUXILIARY
Early Bird Fee: $100
After May 15, 2017: $125

RESIDENT/GRAD STUDENT
Fee: $75

Return to top

SCHEDULE

THURSDAY, JUNE 15, 2017

PRESYMPOSIUM
Location: University of Michigan, Ann Arbor
4:30pm - 6:30pm Poster Presentation with Wine & Cheese Reception, free of charge to attendees

FRIDAY, JUNE 16, 2017

SYMPOSIUM
Location: University of Michigan, Ann Arbor
8:25am - 8:35am Welcome by Dean and Chair
8:35am - 8:45am Introduction
Peter J. Polverini
Session I: Molecular Diagnosis and Biomarkers of Progression
Nisha D'Silva and Gregory T. Wolf, session co-chairs
8:45am - 9:30am HPV – The Emerging Epidemic
Maura L. Gillison
9:30am - 10:10am Precision Molecular Diagnostics and Chemoprevention for Oral Premalignancy
Mark W. Lingen
10:10am - 10:30am Break
10:30am - 11:10am Biomarkers in Head and Neck Cancer
Jeffrey N. Myers
11:10am - 11:25am Clocking-on to the PI3K/mTOR signaling
Cristiane Squarize
11:25am - 11:40am Targeting histones as a new therapeutic strategy
Rogerio Castilho
11:40am - 1:00pm Lunch on your own
Session II: Personalized Treatment
Peter J. Polverini and Thomas E. Carey, session co-chairs
1:00pm - 1:45pm Treatment Selection
Carol R. Bradford
1:45pm - 2:25pm Rationally Integrating Immunotherapy into Head and Neck Cancer: Lessons from the lab and clinic
Robert L. Ferris
2:25pm - 2:45pm Break
2:45pm - 3:20pm Targeting DNA Repair
Nisha J. D’Silva
3:20pm - 3:40pm Stem Cells as Treatment Targets
Mark EP Prince
3:40pm - 3:55pm Type I Interferon and Tumor Immunogenicity
Yu Leo Lei
3:55pm - 4:00pm Conclusion
Nisha J. D’Silva
Return to top

SPEAKERS

Carol R. Bradford, MD

University of Michigan Medical School
4101 Medical Science Building I, SPC 5624
734-764-8175
cbradfor@med.umich.edu

An internationally recognized head and neck cancer researcher and faculty leader, Carol R. Bradford, M.D., M.S., is the executive vice dean for academic affairs for the University of Michigan Medical School. She also holds the Charles J. Krause, M.D., Collegiate Professorship in Otolaryngology and is a professor of otolaryngology-head and neck surgery. A longtime member of the University of Michigan community, Bradford earned her B.S. in cellular and molecular biology, her M.S. in microbiology/immunology and M.D. degrees at U-M. She then completed an otolaryngology-head and neck surgery residency at the U-M before joining the faculty in 1992. She became department chair in 2009, a position she held until she was appointed EVDAA on July 1, 2016. Under her leadership, the department’s faculty grew from 40 to 55 members, and the Otolaryngology Residency Program was rated the nation’s top otolaryngology training program among public institutions, according to the Doximity Residency Navigator. Dr. Bradford specializes in head and neck cancer surgery, focusing her research on identifying and evaluating biomarkers that can predict outcomes. She works to develop therapies to combat certain types of head and neck cancer that are resistant to traditional forms of treatment. She also pioneered the use of sentinel lymph node biopsy as a safe and reliable tool to stage patients with melanoma of the head and neck. She has published nearly 250 peer-reviewed articles. Her many awards include a Distinguished Service Award from the American Academy of Otolaryngology-Head and Neck Surgery in 2007, the Clinical Excellence Award from Castle Connolly National Physician of the Year Awards in 2009 and the University of Michigan Medical School’s Community Service Award in 2010. She was elected as the first woman president of the American Head and Neck Society in 2012. In 2015, she was inducted into the prestigious National Academy of Medicine, formerly the Institute of Medicine. Dr. Bradford currently serves on the board of directors of the American Academy of Otolaryngology-Head and Neck Surgery and as president of the Society of University Otolaryngologists.

Rogerio M. Castilho DDS, MS, PhD

University of Michigan School of Dentistry
1011 N University Ave, Room 2029C
Ann Arbor, MI 48109-1078
(734) 647-2150
rcastilh@umich.edu

Dr. Castilho is an Assistant Professor at the Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry. He earned his D.D.S. at the Pontific Catholic University of Campinas (PUCCAMP-Brazil) and his Master and Ph.D. in Oral Pathology from the University of Sao Paulo (USP). Following, Dr. Castilho completed a 7 years postdoctoral training as a Research Fellow at the National Institute of Dental and Craniofacial Research (NIDCR-NIH). His research focus is on the fields of Epithelial and Cancer Biology. Dr. Castilho’s interest in the molecular circuitries capable of modifying tumor resistance to chemo and radiotherapy led him to study the effects of histone acetylation over cancer stem cells fate and the activation of the NFkB resistance pathway.

Nisha D’Silva BDS, MSD, PhD

University of Michigan School of Dentistry
1011 N. University Avenue, Rm 5217
Ann Arbor, MI 48109-1078
(734) 764-1543
njdsilva@umich.edu

Dr. D’Silva is an oral pathologist, cancer biologist, and educator. She is Associate Chair in the department of Periodontics and Oral Medicine. Dr. D’Silva is the Donald Kerr Endowed Collegiate Professor of Oral Pathology and Professor of Dentistry at the University of Michigan. She is also Associate Professor of Pathology at the University of Michigan Medical School. She is a member of the University of Michigan Comprehensive Cancer Center. Dr. D’Silva is a Diplomate of the American Board of Oral and Maxillofacial Pathology. Her research in head and neck cancer focuses on biomarkers and molecular mechanisms of tumor progression and treatment resistance. Her work has been recognized by several awards including the Rod Cawson Prize from the International Association of Oral Pathologists and the Royal College of Physicians and Surgeons of Glasgow. She also received the Michigan Institute for Clinical and Health Research Distinguished Clinical and Translational Research Mentor award. Dr. D’Silva received her dental degree at the University of Bombay, India, followed by a Residency in Oral and Maxillofacial Pathology and a Master’s degree at Indiana University, Indianapolis. She received her PhD at the University of Washington, Seattle.

Robert L. Ferris, MD, PhD

5117 Centre Avenue; Suite 2.26b
Pittsburgh, PA 15238
(412) 623-1416
ferrrl@upmc.edu

Dr. Ferris completed his training at Johns Hopkins in 2001, focused on head and neck oncologic surgery and cancer immunology. He moved to the University of Pittsburgh, where he is currently UPMC Endowed Professor, Vice-Chair and Chief of Head and Neck Surgery, and Fellowship Director in Head and Neck Oncologic Surgery. At the University of Pittsburgh Cancer Institute, he is Co-Leader of the Cancer Immunology Program and Associate Director for Translational Research. Dr. Ferris serves on the Editorial Boards of JNCI, JCO, Clinical Cancer Research, Cancer Immunology Research and Section Editor for Cancer. He is Editor in Chief of Oral Oncology. Dr. Ferris has published over 250 peer-reviewed manuscripts and in 2015 was elected co-chair of the NCI Head and Neck Steering committee to facilitate prospective clinical trials. Dr. Ferris has authored numerous book chapters and co-edited two textbooks, Salivary Gland Disorders and Master Techniques in Head and Neck Surgery. Dr. Ferris’s NIH-funded laboratory is focused on reversal of immune escape and immunotherapy using monoclonal antibodies and cellular vaccines, leading randomized phase II-III trials of anti-PD-1 and anti-CTLA-4 immunotherapy. He currently chairs the NIH tumor Microenvironment study section. He is PI of several prospective randomized trials, including ECOG 3311, testing radiation dose-deintensification after transoral robotic surgery (TORS) for HPV+ oropharynx cancer, as well as ECOG-ACRIN 3132, using p53 mutational testing in HPV- cancer, to predict response to radiation versus chemoradiation. He is a Principal Investigator of the University of Pittsburgh Specialized Program of Research Excellence (SPORE) grant for translational head and neck research, and a T32 training grant, “Training of Head and Neck Oncologists,” both funded by the National Cancer Institute until 2020.

Maura L. Gillison, MD PhD

Tzagournis Research Facility
The Ohio State University
420 West 12th Ave, Room 690
Columbus, OH 43210
(614) 247-4589
maura.gillison@osumc.edu

Dr. Gillison is a Professor of Medicine and Jeg Coughlin Chair of Cancer Research at The Ohio State University Comprehensive Cancer Center. Recruited to Ohio State in 2009 from the Johns Hopkins University School of Medicine, Dr. Gillison is a head and neck medical oncologist and molecular epidemiologist. Her laboratory focuses on the role of human papillomavirus (HPV) infection in head and neck malignancies. Her work ranges from cohort studies of oral HPV infection to genetic indicators of response to chemoradiotherapy. She has made important research contributions to the fields of tumor virology, cancer biology and epidemiology. In 2000, she was part of the team that first demonstrated that some head and neck squamous cell carcinomas (HNSCCs) are HPV-positive, and that HPV is the causative agent of a subset of head and neck cancer. Her findings have extended previous molecular and epidemiological studies and demonstrated that HPV-positive HNSCCs are a distinct disease at the molecular level that is causally associated with high-risk HPV subtypes. Dr. Gillison is a recipient of the Clinical Investigator Award from the Damon Runyon Cancer Research Institute and in 2012 received the Richard and Hilda Rosenthal Award from the American Association for Cancer Research. She has published extensively in such prestigious journals as the New England Journal of Medicine, Journal of the National Cancer Institute and Journal of Clinical Oncology. Her lab collaborates with the Centers for Disease Control, the National Cancer Institute, the National Institutes of Health and the International Agency for Research on Cancer.

Yu Leo Lei DDS, PhD

1600 Huron Parkway 2355
Ann Arbor, MI 48109
(734) 615-6967
leiyuleo@umich.edu

Dr. Lei is an immunologist-oral pathologist. He is an Assistant Professor of Dentistry and Otolaryngology, Department of Periodontics and Oral Medicine and Department of Otolaryngology - Head and Neck Surgery, the University of Michigan. He is a faculty member of the Graduate Program in Immunology, Translational Oncology Program, Distributed Health Technologies, Head and Neck Oncology Program, and Cancer Biology Program of the U-M Medical School. After his Ph.D. training at the Lineberger Comprehensive Cancer Center, UNC-Chapel Hill, and residency at the University of Pittsburgh Medical Center, he completed his Head and Neck Oncology research fellowship at the University of Pittsburgh Cancer Institute. Before he was recruited to U-M, he served as a research assistant professor at the Department of Otolaryngology, University of Pittsburgh School of Medicine. Dr. Lei’s research group utilizes a spectrum of techniques to reveal the regulatory network of damage-associated molecular patterns (DAMPs)-mediated innate immune detection of cancer. His NIH-funded laboratory focuses on the molecular mechanisms regulating cancer immunogenicity and development of novel vaccine formulations to inhibit cancer-associated immune suppression.

Jeffrey N. Myers MD, PhD

Department of Head and Neck Surgery
The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 1445
Houston, TX 77030-4009
jmyers@mdanderson.org

Dr. Jeffrey N. Myers is the Olive and Hubert Distinguished Professor in Cancer Research. He received his medical (MD) and doctoral (PhD) degrees from the University of Pennsylvania School of Medicine and then completed his residency training in Otolaryngology-Head and Neck Surgery at the University of Pittsburgh. He subsequently completed fellowship training in Head and Neck Surgical Oncology at the University of Texas MD Anderson Cancer Center in 1997, where he has been on the faculty ever since. He is currently Professor and Director of Research in the Department. In addition, Dr. Myers leads a basic and translational research program and his primary research interests are in the role of p53 mutation in oral cancer progression, metastasis and response to treatment.

Mark W. Lingen, DDS, PhD, FRCPath

Department of Pathology
The University of Chicago
5841 South Maryland Avenue, MC 6101
Chicago, IL 60637
773-702-5548
mark.lingen@uchospitals.edu

Mark Lingen is a Professor of Pathology at the University of Chicago Medicine. He completed his dental school training, Oral & Maxillofacial Pathology residency and PhD in Cellular and Molecular Pathology at Northwestern University. Dr. Lingen is the Editor in Chief of the journal Oral Surgery, Oral Medicine, Oral Pathology Oral Radiology (TripleO). His research dealing with the molecular diagnostics and oral cancer prevention has resulted in more than 150 publications. Dr. Lingen is a Diplomate of the American Board of Oral & Maxillofacial Pathology and is a Fellow of the American College of Dentists, the International College of Dentists, and the Royal College of Pathologists.

Peter J. Polverini, DDS, DMSc

University of Michigan School of Dentistry
1011 North University Avenue, Rm G020A
Ann Arbor, MI 48019
(734) 764-1543
neovas@umich.edu

Dr. Polverini is the Jonathan Taft Distinguished University Professor of Dentistry and a Former Dean, University of Michigan Dental School and Professor of Pathology, University of Michigan Medical School. He has a distinguished scientific career in the field of vascular and cancer biology where he has long been a leader and influential figure. More recently, he has focused his attention on the educational and workforce implications of new integrated care delivery models and the emerging personalized health care environment. Dr. Polverini is a Diplomate of the American Board of Oral and Maxillofacial Pathology, Fellow of the American Academy of Oral and Maxillofacial Pathology, Fellow of the American Association for the Advancement of Sciences, a recipient of the Distinguished Scientist Award in Oral Medicine and Pathology from the International Association for Dental Research, and past President of the American Association for Dental Research. Dr. Polverini is an elected member of the National Academy of Medicine.

Mark Prince MD, FRCS(C)

Department of Otolaryngology-HNS
1904 Taubman Center
1500 East Medical Center Drive
Ann Arbor MI, 48109
(734) 936-9178
mepp@med.umich.edu

Dr. Mark Prince earned his medical degree at Dalhousie University Medical School in Halifax, Nova Scotia, and then served with the Canadian Armed Forces as a medical officer, receiving specialized training in hyperbaric and diving medicine. Dr. Prince returned to Dalhousie University and completed a residency in otolaryngology head and neck surgery, followed by a two-year fellowship in advanced head and neck oncology and microvascular reconstructive surgery at the University of Michigan. He joined the University of Michigan faculty in 2000, and is actively involved in resident and medical student education, serving as his department's residency program director till 2016. Dr. Prince is the Chief of the Department of Otolaryngology-HNS Head and Neck Oncology Division. He remains an active reconstructive and head and neck oncologic surgeon. In collaboration with researchers in Stanford his research laboratory published the first report of the identification of cancer stem cells in head and neck squamous cell cancer. Recently he has been involved in several studies investigating cancer stem cell behavior as well as an exciting project focused on developing an anti-cancer stem cell vaccine.

Cristiane Squarize, DDS, MS, PhD

Department of Periodontics and Oral Medicine
1011 N University Ave, Rm 3210
University of Michigan School of Dentistry
Ann Arbor, MI 48109-1078
(734) 615-3406
csquariz@umich.edu

Dr. Squarize is an Assistant Professor at the Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry. She earned her D.D.S. at the Pontific Catholic University of Campinas (PUCCAMP) and her Master and Ph.D. in Oral Pathology from the University of Sao Paulo (USP). Dr. Squarize was a Research Fellow at the National Institute of Dental and Craniofacial Research (NIDCR) and completed postdoctoral training at the National Institutes of Health (NIH). Her publications and lectures are focused on the fields of Regenerative Medicine and Head and Neck Cancer as it relates to tobacco, HPV infection, novel cancer treatment, and resistance to therapy. Dr. Squarize is a Faculty at the University of Michigan, Robert Wood Johnson Scholar, member of the International Association of Dental Research (IADR) and the American Dental Research Association (AADR).

Return to top

CONTINUING EDUCATION
DENTAL & MEDICAL

The University of Michigan School of Dentistry designates this activity for 8 hours of continuing dental education credits. Credit letters are available at the conclusion of the course. The University of Michigan is an ADA CERP recognized provider. ADA CERP is a service of the American Dental Association to assist dental professional in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Michigan Medical School and the University of Michigan School of Dentistry. The University of Michigan Medical School is accredited by the ACCME to provide continuingmedical education for physicians. The University of Michigan Medical School designates this live activity for a maximum of 6 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Refund Policy: A full refund will be granted if cancellation is received four weeks prior to the start of the course.

Copyright © 2017. The Regents of the University of Michigan. A Non-discriminatory, Affirmative Action Employer. Regents of the University of Michigan: Michael J. Behm, Mark J. Bernstein, Laurence B. Deitch, Shauna Ryder Diggs, Denise Ilitch, Andrea Fischer Newman, Andrew C. Richner, Katherine E. White, Mark S. Schlissel, ex officio.

TRAVEL INFO

LOCAL HOTELS

FROM DETROIT METRO AIRPORT TO ANN ARBOR

The trip between the Detroit Metro Airport and Ann Arbor takes about 20-30 minutes.

Taxi costs around US$ 50. They usually take 3 people (it is not necessary to make reservations for the taxi).

The most economical option is to take a shuttle.

Another alternative (a bit more expensive) is to take the Metrocar Services. The driver will wait for you at the baggage claim, pick up your bags, and bring you to Ann Arbor (they generally take up to 3 people).

WEATHER

June is one of the hottest months for Ann Arbor. Temperatures range from 62°F to 83°F. Precipitation can range from light rain to thunderstorms.

RESTAURANTS

Restaurants in Ann Arbor

PARKING

Parking in Ann Arbor

CURRENCY

Currency Converter

MAP